Now showing items 1-20 of 41

    • Advances in the treatment of gastrointestinal stromal tumours. 

      Judson, I; Demetri, G (2007-09)
      Imatinib, a selective tyrosine kinase inhibitor, is currently the standard of care first-line treatment for unresectable or metastatic gastrointestinal stromal tumour (GIST), improving survival time and delaying disease ...
    • AKT Inhibition in Solid Tumors With AKT1 Mutations. 

      Hyman, DM; Smyth, LM; Donoghue, MTA; Westin, SN; Bedard, PL; Dean, EJ; Bando, H; El-Khoueiry, AB; Pérez-Fidalgo, JA; Mita, A; Schellens, JHM; Chang, MT; Reichel, JB; Bouvier, N; Selcuklu, SD; Soumerai, TE; Torrisi, J; Erinjeri, JP; Ambrose, H; Barrett, JC; Dougherty, B; Foxley, A; Lindemann, JPO; McEwen, R; Pass, M; Schiavon, G; Berger, MF; Chandarlapaty, S; Solit, DB; Banerji, U; Baselga, J; Taylor, BS (2017-07)
      Purpose AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363, an ATP-competitive pan-AKT kinase inhibitor, to determine the preliminary ...
    • Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series. 

      Frezza, AM; Jones, RL; Lo Vullo, S; Asano, N; Lucibello, F; Ben-Ami, E; Ratan, R; Teterycz, P; Boye, K; Brahmi, M; Palmerini, E; Fedenko, A; Vincenzi, B; Brunello, A; Desar, IME; Benjamin, RS; Blay, JY; Broto, JM; Casali, PG; Gelderblom, H; Grignani, G; Gronchi, A; Hall, KS; Mir, O; Rutkowski, P; Wagner, AJ; Anurova, O; Collini, P; Dei Tos, AP; Flucke, U; Hornick, JL; Lobmaier, I; Philippe, T; Picci, P; Ranchere, D; Renne, SL; Sbaraglia, M; Thway, K; Wagrodzki, M; Wang, W-L; Yoshida, A; Mariani, L; Kawai, A; Stacchiotti, S (2018-09-13)
      Importance:Epithelioid sarcoma (ES) is an exceedingly rare malignant neoplasm with distinctive pathologic, molecular, and clinical features as well as the potential to respond to new targeted drugs. Little is known on the ...
    • APC/C is an essential regulator of centrosome clustering. 

      Drosopoulos, K; Tang, C; Chao, WCH; Linardopoulos, S (2014-04-22)
      Centrosome amplification has been extensively associated with cancer. Cancer cells with extra centrosomes have the ability to cluster the extra centrosomes and divide in a bipolar fashion. Although a number of proteins ...
    • Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. 

      Camidge, DR; Kim, HR; Ahn, M-J; Yang, JC-H; Han, J-Y; Lee, J-S; Hochmair, MJ; Li, JY-C; Chang, G-C; Lee, KH; Gridelli, C; Delmonte, A; Garcia Campelo, R; Kim, D-W; Bearz, A; Griesinger, F; Morabito, A; Felip, E; Califano, R; Ghosh, S; Spira, A; Gettinger, SN; Tiseo, M; Gupta, N; Haney, J; Kerstein, D; Popat, S (2018-11)
      BACKGROUND:Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, has robust efficacy in patients with ALK-positive non-small-cell lung cancer (NSCLC) that is refractory to crizotinib. The efficacy of ...
    • CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. 

      Costa-Cabral, S; Brough, R; Konde, A; Aarts, M; Campbell, J; Marinari, E; Riffell, J; Bardelli, A; Torrance, C; Lord, CJ; Ashworth, A (2016-01)
      Activating KRAS mutations are found in approximately 20% of human cancers but no RAS-directed therapies are currently available. Here we describe a novel, robust, KRAS synthetic lethal interaction with the cyclin dependent ...
    • CHK1 Inhibition Radiosensitizes Head and Neck Cancers to Paclitaxel-Based Chemoradiotherapy. 

      Barker, HE; Patel, R; McLaughlin, M; Schick, U; Zaidi, S; Nutting, CM; Newbold, KL; Bhide, S; Harrington, KJ (2016-09)
      Head and neck squamous cell carcinoma (HNSCC) is a leading cause of cancer-related deaths, with increasingly more cases arising due to high-risk human papillomavirus (HPV) infection. Cisplatin-based chemoradiotherapy is a ...
    • Clinical benefit of antiangiogenic therapy in advanced and metastatic chondrosarcoma. 

      Jones, RL; Katz, D; Loggers, ET; Davidson, D; Rodler, ET; Pollack, SM (2017-08-29)
      Chondrosarcoma is the most common bone sarcoma in adults. Conventional chondrosarcoma, the commonest histological subtype, is largely resistant to anthracycline-based chemotherapy. There have been anecdotal reports of ...
    • Dual Targeting of PDGFRα and FGFR1 Displays Synergistic Efficacy in Malignant Rhabdoid Tumors. 

      Wong, JP; Todd, JR; Finetti, MA; McCarthy, F; Broncel, M; Vyse, S; Luczynski, MT; Crosier, S; Ryall, KA; Holmes, K; Payne, LS; Daley, F; Wai, P; Jenks, A; Tanos, B; Tan, A-C; Natrajan, RC; Williamson, D; Huang, PH (2016-10)
      Subunits of the SWI/SNF chromatin remodeling complex are mutated in a significant proportion of human cancers. Malignant rhabdoid tumors (MRTs) are lethal pediatric cancers characterized by a deficiency in the SWI/SNF ...
    • Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1. 

      Aarts, M; Sharpe, R; Garcia-Murillas, I; Gevensleben, H; Hurd, MS; Shumway, SD; Toniatti, C; Ashworth, A; Turner, NC (2012-06)
      Inhibition of the protein kinase WEE1 synergizes with chemotherapy in preclinical models and WEE1 inhibitors are being explored as potential cancer therapies. Here, we investigate the mechanism that underlies this synergy. ...
    • GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors. 

      Morandi, A; Martin, L-A; Gao, Q; Pancholi, S; Mackay, A; Robertson, D; Zvelebil, M; Dowsett, M; Plaza-Menacho, I; Isacke, CM (2013-06)
      Most breast cancers at diagnosis are estrogen receptor-positive (ER(+)) and depend on estrogen for growth and survival. Blocking estrogen biosynthesis by aromatase inhibitors has therefore become a first-line endocrine ...
    • Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma. 

      Tucker, ER; Tall, JR; Danielson, LS; Gowan, S; Jamin, Y; Robinson, SP; Banerji, U; Chesler, L (2017-08)
      Targeted inhibition of anaplastic lymphoma kinase (ALK) is a successful approach for the treatment of many ALK-aberrant malignancies; however, the presence of resistant mutations necessitates both the development of more ...
    • In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells. 

      Al-Saffar, NMS; Agliano, A; Marshall, LV; Jackson, LE; Balarajah, G; Sidhu, J; Clarke, PA; Jones, C; Workman, P; Pearson, ADJ; Leach, MO (2017-01)
      Recent experimental data showed that the PI3K pathway contributes to resistance to temozolomide (TMZ) in paediatric glioblastoma and that this effect is reversed by combination treatment of TMZ with a PI3K inhibitor. Our ...
    • Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer. 

      Califano, R; Greystoke, A; Lal, R; Thompson, J; Popat, S (2017-09)
      Anaplastic lymphoma kinase rearrangement (ALK+) occurs in approximately 2-7% of patients with non-small cell lung cancer (NSCLC), contributing to a considerable number of patients with ALK+ NSCLC worldwide. Ceritinib is a ...
    • Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. 

      Chong, IY; Aronson, L; Bryant, H; Gulati, A; Campbell, J; Elliott, R; Pettitt, S; Wilkerson, P; Lambros, MB; Reis-Filho, JS; Ramessur, A; Davidson, M; Chau, I; Cunningham, D; Ashworth, A; Lord, CJ (2018-10)
      OBJECTIVE:Oesophageal cancer is the seventh most common cause of cancer-related death worldwide. Disease relapse is frequent and treatment options are limited. DESIGN:To identify new biomarker-defined therapeutic approaches ...
    • Modeling Therapy Resistance in BRCA1/2-Mutant Cancers. 

      Dréan, A; Williamson, CT; Brough, R; Brandsma, I; Menon, M; Konde, A; Garcia-Murillas, I; Pemberton, HN; Frankum, J; Rafiq, R; Badham, N; Campbell, J; Gulati, A; Turner, NC; Pettitt, SJ; Ashworth, A; Lord, CJ (2017-09)
      Although PARP inhibitors target BRCA1- or BRCA2-mutant tumor cells, drug resistance is a problem. PARP inhibitor resistance is sometimes associated with the presence of secondary or "revertant" mutations in BRCA1 or BRCA2 ...
    • The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer. 

      Middleton, G; Crack, LR; Popat, S; Swanton, C; Hollingsworth, SJ; Buller, R; Walker, I; Carr, TH; Wherton, D; Billingham, LJ (2015-12)
      BACKGROUND:The management of NSCLC has been transformed by stratified medicine. The National Lung Matrix Trial (NLMT) is a UK-wide study exploring the activity of rationally selected biomarker/targeted therapy combinations. ...
    • Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib. 

      Lankheet, NAG; Desar, IME; Mulder, SF; Burger, DM; Kweekel, DM; van Herpen, CML; van der Graaf, WTA; van Erp, NP (2017-10)
      AIM:Fixed dose oral tyrosine kinase inhibitors imatinib, sunitinib and pazopanib show a high interpatient variability in plasma exposure. A relationship between plasma exposure and treatment outcome has been established, ...
    • An orally bioavailable Chk1 inhibitor, CCT244747, sensitizes bladder and head and neck cancer cell lines to radiation. 

      Patel, R; Barker, HE; Kyula, J; McLaughlin, M; Dillon, MT; Schick, U; Hafsi, H; Thompson, A; Khoo, V; Harrington, K; Zaidi, S (2017-03)
      PURPOSE:Chk1 inhibition increases cell sensitivity to both chemotherapy and radiotherapy in several tumour types and is, therefore, a promising anti-cancer approach. Although several Chk1 inhibitors have been developed, ...
    • Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. 

      Benson, C; Ray-Coquard, I; Sleijfer, S; Litière, S; Blay, J-Y; Le Cesne, A; Papai, Z; Judson, I; Schöffski, P; Chawla, S; Gil, T; Piperno-Neumann, S; Marréaud, S; Dewji, MR; van der Graaf, WTA (2016-07)
      Uterine sarcomas are a group of mesenchymal tumours comprising several histologies. They have a high recurrence rate following surgery, modest outcome to systemic therapy, and poor overall survival. Pazopanib is a ...